Business Wire

PA-FORE-BIOTHERAPEUTICS

18.11.2023 00:56:35 CET | Business Wire | Press release

Share
FORE Biotherapeutics Announces Oral Presentation at SNO 2023 Reporting Updated Phase 1/2a Results for Plixorafenib in BRAF V600 Advanced Solid Tumors, Including Novel Data for Patients with BRAF V600 Primary CNS Tumors

FORE Biotherapeutics today reported updated safety and efficacy data from the Phase 1/2a clinical trial evaluating plixorafenib (FORE8394; PLX8394), a novel, investigational, small-molecule, next-generation, orally available selective inhibitor of BRAF alterations. The results continue to demonstrate promising single-agent activity against BRAF V600-mutated tumors, including primary central nervous system tumors (PCNSTs), as presented at the Society for Neuro-Oncology (SNO) 2023 Annual Meeting, being held November 15-19, 2023, in Vancouver, Canada.

“The updated data from our Phase 1/2a study continues to reinforce plixorafenib’s differentiated clinical profile in patients harboring BRAF V600 mutations,” said Stacie Shepherd, MD, PhD, and Chief Medical Officer of FORE. “The data presented today at SNO 2023 demonstrate deep and durable confirmed responses in MAPK inhibitor-naïve patients, including a 67% overall response rate in patients with primary central nervous system tumors. I look forward to further elucidating plixorafenib’s potential in our ongoing, global Phase 2 FORTE study.”

“These results continue to demonstrate that plixorafenib has a favorable safety and efficacy profile compared to the currently approved BRAF/MEK inhibitors and investigational pan-RAF inhibitors,” shared Macarena de la Fuente, MD, Associate Professor and Chief of Neuro-oncology at the University of Miami Sylvester Comprehensive Cancer Center. “I am excited to share these data today with the medical community and I look forward to the further study of plixorafenib to address the high unmet need of patients living with these difficult to treat cancers.”

Key Findings from the Phase 1/2a Study

Safety and Tolerability

As of the data cutoff date of September 6, 2023, 113 patients have received plixorafenib under continuous dosing until disease progression and are included in the safety population.

  • Plixorafenib continues to demonstrate a favorable tolerability profile with a low frequency of symptomatic treatment emergent adverse events (TEAEs) relative to approved BRAF/MEK inhibitors
  • The safety profile in patients with PCNSTs (N=22) was consistent with that observed in the overall population
    • Headache was the only symptomatic Grade ≥3 treatment emergent AE occurring in >5% of patients
  • At the recommended Phase 2 dose (plixorafenib 900mg QD with PK booster: cobicistat 150mg QD), dose optimization maximizes dose intensity early in treatment with:
    • No DLTs
    • Most common laboratory abnormality TEAEs are predominantly Grade 1-2
    • Symptomatic TEAEs were almost all Grade 1

Efficacy

  • Among the 9 MAPKi-naïve patients with V600-mutated PCNSTs, 6 achieved a response for an ORR of 66.7% (95% CI: 29.9, 92.5), all of which were confirmed responses
    • mDOR was 13.9 months (range: 3.7, 32.3) with 4/6 (67%) of responders having DOR of 6 months or longer
    • mPFS was not yet reached in patients with low grade glioma and glioneuronal tumors (range: 1.6, 27.8+ months; n=4) and 6.7 months (range: 2.8, 34.1 months; n=5) in high grade gliomas
  • Among the 24 MAPKi-naïve patients with V600-mutated advanced solid tumors, 10 had a response for an ORR of 41.7%, all of which were confirmed responses
    • mDOR was 17.8 months (range: 3.7, 59.2)
  • Median time to response was 3.5 months in patients with V600-mutated solid tumors, including those treated with prior MAPK inhibitor

About Plixorafenib (FORE8394; PLX8394)

Plixorafenib is an investigational, novel, small-molecule, next-generation, orally available selective inhibitor of mutated BRAF. It was designed to target a wide range of BRAF mutations while sparing wild-type forms of RAF. Preclinical studies and clinical trials have shown that its unique mechanism of action effectively inhibits not only the constitutively active BRAF V600 monomers targeted by first-generation RAF inhibitors but also disrupts constitutively active dimeric BRAF class 2 mutants, fusions, splice variants and others. Unlike first-generation RAF inhibitors, plixorafenib does not induce paradoxical activation of the RAF/MEK/ERK pathway. As a “paradox breaker,” plixorafenib could therefore treat acquired resistance to current RAF inhibitors and, more generally, yield improved safety and more durable efficacy than first-generation RAF inhibitors.

Plixorafenib was granted Orphan Drug Designation by the U.S. Food and Drug Administration in March 2023 for the treatment of primary CNS malignancies. In September 2022, the Agency granted plixorafenib Fast Track Designation for the treatment of patients with cancers harboring BRAF Class 1 (V600) and Class 2 alterations (including fusions) who have exhausted prior therapies.

Plixorafenib is currently being evaluated in Phase 1/2a clinical trial in patients with advanced solid tumors (including brain and spinal cord tumors) with activating BRAF alterations. Interim clinical data presented at ESMO 2022, ASCO 2023 and SNO 2023 provided evidence of durable anti-tumor activity in patients with BRAF-altered cancers.

About Fore Biotherapeutics

Fore Bio is a precision oncology company dedicated to developing innovative treatments that provide a better outcome for cancer patients. Its lead asset plixorafenib (FORE8394; PLX8394) is a Class 1/V600 and 2 BRAF inhibitor with demonstrated clinical safety and early efficacy signals in an ongoing Phase 1/2a clinical trial. Leveraging a proprietary functional genomics platform that can screen a wide range of known mutations for cancer-driving genes, the Fore Bio research and development team is optimizing drug development by identifying existing compounds with known clinical profiles and a clear path through clinical development to advance new medicines for patients without treatment options. For more information, please visit www.fore.bio or follow us on Twitter and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231117112617/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel18.11.2026 18:00:00 CET | Press release

Four-year global partnership makes WHOOP an Official Partner of Formula 1 bringing physiological insights into the broadcast beginning in 2027 WHOOP, the human performance brand, today announced a four-year global partnership with Formula 1, becoming the Official Health & Fitness Wearable Partner of Formula 1 and the first consumer wearable approved by the FIA for in-race use. Beginning in 2027, the partnership will bring continuous physiological monitoring to one of the world's most demanding sports, helping drivers and teams better understand how their bodies respond to the demands of competition while giving fans a new perspective on the human performance behind the wheel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118567291/en/ WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel WHOOP is working to bring fans closer to the action than ever before, with Formula 1 integrating real-time physi

Future Health Launches Academy to Translate Life Sciences Advances Into Strategic Action18.11.2026 15:37:00 CET | Press release

Future Health Academy will build knowledge and connect expertise among health and life sciences professionals in Abu Dhabi and internationally. The Academy will support two-way knowledge exchange, bringing global expertise to Abu Dhabi while creating opportunities to share Abu Dhabi’s knowledge, expertise and innovation with the world. Inaugural course brought together senior leaders from government, healthcare, research, and industry with local and international scientific experts. Future Health - A Global Initiative by Abu Dhabi has launched the Future Health Academy as part of its year-round programme, designed to build knowledge, connect expertise and create opportunities for collaboration among health and life sciences professionals in Abu Dhabi and internationally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118051527/en/ The Future Health Academy will build knowledge and connect expertise among health and life s

Soracom Launches Physical AI Suite, Bringing Secure Connectivity and Remote Operations to Robots and Autonomous Machines18.11.2026 15:30:00 CET | Press release

Soracom suite combines existing platform services for physical AI, available worldwide Soracom, Inc. (TSE: 147A), a cloud-native IoT platform providing connectivity, cloud integration, and AI services for the Internet of Things, today announced Soracom Physical AI Suite, a set of Soracom platform services combined to connect, protect, and manage physical AI systems such as robots, autonomous mobile machines, and industrial equipment. Soracom Physical AI Suite is the company's second suite, following Soracom Automotive Suite announced in July 2026. Each suite brings together Soracom platform services commonly used for a particular type of deployment, organizing them into a single system. A team starting a new deployment begins from that system instead of selecting and assembling services one at a time. The suite is designed for companies that develop or deploy robots and other physical AI systems and for companies that operate connected equipment in industries including manufacturing, l

Variational Raises $110M Series B at $1.5B Valuation To Scale On-Chain Access To Global Markets18.11.2026 15:23:00 CET | Press release

The raise follows the rapid growth of swaps, Variational’s new instrument bringing liquidity from traditional finance on-chain. Variational, a protocol for on-chain derivatives trading, has announced a $110M Series B raise at a $1.5B valuation led by Bain Capital Crypto with support from Dragonfly, HSG, Peak XV, 50T Funds, and more. Since launching in early 2025, the platform has processed $475B+ in trading volume and accumulated $1.3B+ in open interest across 100k+ accounts. More than half of daily volume on the platform is now on traditional markets. The raise will fund the platform’s continued growth, allowing Variational to list hundreds more markets and lift open interest caps that traders increasingly hit. Omni, a trading platform built on Variational, offers leveraged trading on 550+ crypto and traditional markets. Unlike other on-chain trading platforms, Omni aggregates liquidity from both traditional and on-chain markets. This model allowed the platform to launch “swaps” in Se

Xsolla Connects Players, Brands, and Video Game Audiences Through Rewarded Engagement18.11.2026 15:00:00 CET | Press release

Players Can Choose Their Quests, Developers Get Measurable Results From Their Games, and Advertisers Get Verified Insight From Players Who Choose to Share Xsolla (USA), Inc., a global commerce company, announces Xsolla Ads, a rewarded marketing solution connecting brands with game audiences through quests players choose to take part in. Studios generate revenue beyond player purchases while brands drive measurable engagement, acquisition, and purchases. Players choose which campaigns to participate in and which rewards to receive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117947414/en/ Graphic: Xsolla Players see Xsolla Ads where they already are, including the Xsolla App, game web shops, branded pages on Xsolla, Xsolla Choice surveys, and an opt-in Offerwall. Quests are triggered by game events, such as reaching a new level or season, so studios connect campaigns to what players already do in their games. Completed

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye